European Archives - Page 1330 of 1449 - European Medical Journal

EMJ

Physical Exercise Combats Depression Post Heart Attack

UNIQUE data has shed light on the mental health of individuals who have experienced a heart attack. The analysis, which used the data collected from…

EMJ

Functional Cardiac Muscle Cells can be Successfully Regenerated

BIOENGINEERED human hearts are becoming a reality after a team of researchers successfully generated cardiomyocytes (cardiac muscle cells)…

EMJ

New Congress on Thrombosis and Haemostasis

Amsterdam, The Netherlands: The very first ECTH will be held at the World Forum in The Hague, The Netherlands, from 28 – 30 September 2016.

EMJ

MammaPrint Genetic Test Can Reduce Use of Post-Surgery Chemotherapy among Early-Stage Breast Cancer Patients

NEW ORLEANS — Among patients with early-stage breast cancer who were considered at high risk for disease recurrence based on clinical and biological…

EMJ

Norgine Expands Its Partnership with Apharm to Commercialise ZIVEREL® in New European Countries

LONDON, 15 April 2015, 07:00 AM BST: Norgine B.V. announced today that it has expanded its agreement with Apharm s.r.l. to distribute ZIVEREL® in…

EMJ

Heart Attack Patients More Depressed but Get Less Antidepressants

Athens, Greece – 16 April 2016: Heart attack patients are more depressed but are less often prescribed antidepressants than people who have not had a…

From Bench to Bedside: Targeting the IL-1β Pathway in Autoinflammatory Diseases

Prof Gerd Horneff opened the symposium with a summary of the recent advances in the understanding of the role of interleukin (IL)-1β in the pathogenesis…

EMJ Rheumatology 3 [Suppl 5] 2016

American College of Rheumatology Association of Rheumatology Health Professionals (ACR/ARHP) 2015 Meeting Highlights: New Data on Canakinumab

EMJ Rheumatology 3 [Suppl 4] 2016

This symposium explored the pathogenesis and treatment approaches for autoinflammatory diseases, including the role of IL-1β and anti-IL-1β therapeutics…

American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) 2015 Meeting Highlights: New Data on Canakinumab

nterleukin (IL)-1 is a messenger for the regulation of inflammatory responses, but it can be harmful when in excess, such as in the inflammation observed…